Aims/hypothesis The genetic determinants of diabetic nephropathy remain poorly understood. We aimed to identify novel susceptibility genes for diabetic nephropathy. Methods We performed a genome-wide association study using 1000 Genomes-based imputation to compare type 1 diabetic nephropathy cases with proteinuria and with or without renal failure with control patients who have had diabetes for more than 15 years and no evidence of renal disease.
rs1326934-C allele was less frequent in cases than in controls (0.34 vs 0.43) and was associated with a decreased risk for diabetic nephropathy (OR 0.70; 95% CI 0.60, 0.82). However, this association was not observed in a second stage with two additional diabetic nephropathy cohorts, the All IrelandWarren 3-Genetics of Kidneys in Diabetes UK and Republic of Ireland (UK-ROI; p=0.15) and the Finnish Diabetic Nephropathy (FinnDiane; p=0.44) studies, totalling 2,142 cases and 2,494 controls. Altogether, the random-effect metaanalysed rs1326934-C allele OR for diabetic nephropathy was 0.83 (95% CI 0.72, 0.96; p=0.009).
Conclusions/interpretation These data suggest that SORBS1 might be a gene involved in diabetic nephropathy. 
Introduction
Diabetic nephropathy is a frequent condition affecting a substantial proportion of diabetic patients, and is a leading cause of end-stage renal disease. The determinants of diabetic nephropathy are complex and include genetic factors, as supported by a strong familial aggregation of diabetic nephropathy [1] .
The precise nature of the genetic burden involved in diabetic nephropathy remains poorly understood. An alternative approach to candidate gene studies is to perform unbiased genome-wide association studies (GWAS). To date, only a small number of GWAS for diabetic nephropathy have been performed. Recently, the Genetics of Nephropathy an International Effort (GENIE) consortium identified two loci associated with a population attributable risk of 0.5-10.5% [2] . Therefore, additional studies are needed to discover novel loci associated with diabetic nephropathy.
The aim of our research was to conduct a GWAS in a largescale case-control study including French and Danish patients, based on the latest 1000 Genomes (1000G) imputation techniques, and to replicate our findings in available cohorts of patients with type 1 diabetes from European ancestry.
Methods
Studied participants were of white European origin [2] [3] [4] . Briefly, patients were classified as cases or controls at the time of recruitment in all but the Finnish Diabetic Nephropathy (FinnDiane) study, where they were selected among a population-based consecutive collection of people with type 1 diabetes, and the nephropathy status of the patients was defined based on the latest available data. All cohorts were multi-centric except the single-centre LEwis blood type and Angiotensin Converting Enzyme (LEACE) study. Local ethics committees approved the study protocols. All participants gave written informed consent.
Phenotypic determination
Type 1 diabetes Type 1 diabetes was diagnosed using American Diabetes Association criteria: rapid definitive insulin requirement (within 1 year of diagnosis) and age at diabetes onset below 31 or 36 years, differing according to each cohort (Electronic supplementary material [ESM] Table 1 ).
Diabetic nephropathy status Phenotype determination was based on the clinical criteria proposed by the Genetics of Kidneys in Diabetes US (US-GoKinD) study: cases had proteinuria with or without renal failure. Proteinuria was uniformly defined on at least two of three sterile urine collections (ESM Table 1 ). Controls had long-term duration of diabetes (over 15 years), normo-albuminuria without renal failure and were not prescribed drugs that block the renin-angiotensin system. Microalbuminuric patients were not considered for the current analyses.
Study organisation
The general research strategy adopted in this project is summarised in ESM Fig. 1 . Brief descriptions of the studied cohorts and patients can be found in ESM Tables 1 and 2 .
We ultimately assessed expression of the identified gene in a post-hoc analysis of micro-dissected glomerular and tubule samples [5] .
Genotype, quality control and imputation
Genotyping platforms, quality control and imputation are detailed in ESM Methods.
Statistical analysis
A logistic regression analysis was conducted to evaluate the association of each imputed single nucleotide polymorphism (SNP) with diabetic nephropathy under an additive genetic model (allele dosage was used as the covariate for characterising the tested SNP). Analyses were adjusted for age, sex and the first four principal components derived from the genome-wide genotyped SNPs computed by the Eigenstrat programme (http://www.hsph.harvard.edu/alkes-price/ software/) [6] . Association analyses were performed using the mach2dat (version 1.0.19) software (http://www.unc.edu/ yunmli/software.html).
All SNPs with suggestive evidence of an association with diabetic nephropathy ( p<10
) were moved forward in the first-stage study. The centre-and sex-adjusted association of these SNPs with diabetic nephropathy was investigated using the SNPTEST programme (https://mathgen.stats.ox.ac.uk/ genetics_software/snptest/snptest.html#introduction).
In the second-stage samples, the association of candidate SNP with diabetic nephropathy was tested using the CochranArmitage (CA) trend test. ORs derived from application of the CA test in the four case-control samples were finally combined into a random-effect model based meta-analysis using the GWAMA programme (http://www.well.ox.ac.uk/gwama/ download.shtml) [7] .
Results

Discovery analysis
None of the 11,133,962 tested SNPs achieved the statistical threshold of 5×10 −8 for declaring genome-wide significance (ESM Figs 2 and 3 ). All SNPs with suggestive evidence for association at p<10 −5 (n=46) were selected for further association testing in a first independent sample of 820 cases and 885 controls in the US-GoKinD study (ESM Fig. 1 ).
First-stage study
After Bonferroni correction, three SNPs demonstrated significant association with diabetic nephropathy: rs11188343 ( p= 9.06×10 ) and rs4917695 ( p= 1.27×10 −4 ) (ESM Table 3 ). These SNPs mapped to the SORBS1 gene and were in near complete linkage disequilibrium (r 2~1 ). In the discovery GWAS, the minor rs1326934-C allele was less frequent in cases than in controls (0.34 vs 0.43) and was associated with a decreased risk for diabetic nephropathy (OR 0.70 [95% CI 0.60, 0.82]; p=7.87×10 −6 ). In the first-stage population, a consistent association was observed with the rs1326934-C allele at a lower frequency in cases (combined statistical evidence for association of p=3.52×10 −9 ) compared with controls ( ). However, this association was statistically heterogeneous across the four samples ( p=3.94×10 ) and the random-effect meta-analysed OR for diabetic nephropathy was, therefore, 0.83 (95% CI 0.72, 0.96; p=0.009). When FinnDiane patients were excluded the metaanalysed OR was 0.795 (95% CI 0.733, 0.861; p=2.40×10
−8
).
Gene expression analysis
SORBS1 gene overexpression was observed in tubules of type 2 diabetes patients compared with controls (Fig. 1a , ESM Tables 4  and 5 ). We also observed a significant inverse correlation between SORBS1 expression and estimated glomerular filtration rate (eGFR) (R=−0.493; p=1.44×10 −3 ) (Fig. 1b) . Among the other genes mapped within 250 kb of rs1326934, SORBS1 demonstrated the strongest correlation with eGFR in both control and diabetic nephropathy tubule samples (Fig. 1c) . Furthermore, at a protein level, sorbin and SH3 domaincontaining protein 1(SORBS1) was also highly expressed in renal tubules and medium expressed in glomeruli (www. proteinatlas.org).
Discussion
In this study, a multi-stage based GWAS looked for novel susceptibility genes associated with diabetic nephropathy in patients with type 1 diabetes. Although we did not detect any new loci passing genome-wide significance, we observed promising evidence for an association between SORBS1 rs1326934 (or any SNP in complete linkage disequilibrium with it) and diabetic nephropathy in three of four of the studied populations. Given the frequency of the risk allele observed in our control populations (~0.55) and the associated OR for diabetic nephropathy (~1.25), the population attributable risk of the identified polymorphisms would be 12%.
No association was observed in the Finish population, which exhibited a marked difference in allele frequency at the candidate SNP compared with the three other studied populations. We further interrogated databases with genome-wide genotype and gene expression but did not observe any association in monocytes, macrophages, hepatocytes, adipocytes [8] or endothelial cells [9] with SORBS1 gene expression. Nevertheless, the SORBS1 rs1188343 (in complete linkage disequilibrium with the rs1326934) was predicted in the RegulomeDB database (http://regulome.stanford.edu) to be located at a potential binding site for either RFX3 or histone interaction.
The sorbin protein, coded by SORBS1, was found to be differentially upregulated in glomeruli of rats with diabetic nephropathy compared with rats without diabetic nephropathy [10] . High tubular and moderate glomerular expression of sorbin protein was observed in human kidney samples. These findings from type 2 diabetes patients provide additional support for the association of SORBS1 with diabetic nephropathy. Gene expression changes of SORBS1 were easier to detect in tubules, as SORBS1 has a higher tubular expression. Although SORBS1 expression was significantly upregulated only in tubules, we cannot exclude the importance of glomerular SORBS1. Diabetic nephropathy not only involves glomeruli but also tubules [11] , and genes identified through GWAS are likely to impact both renal structures.
The function of sorbin is not fully established but we speculate it plays a key role in several processes involved in diabetic nephropathy, including insulin resistance and cytoskeleton architecture. Sorbin acts in the genesis of stress fibres and might, therefore, be involved in podocyte alterations of the slit diaphragm barrier.
The lack of homogenous replicated associations in our work is unlikely to be due to clinical heterogeneity of the studied populations as the same definitions for type 1 diabetes and diabetic nephropathy were used. Conversely, the different patterns of allelic heterogeneity and linkage disequilibrium across European populations may explain the lack of replication of the SORBS1 signal in the Finnish population. Characterising the exact variability at the SORBS1 locus is needed to validate SORBS1 as a new susceptibility gene for diabetic nephropathy and to identify the disease-associated functional variant(s).
The main limitation of the present study is its design. We adopted a multi-stage strategy using all available GWAS resources imputed for 1000G reference dataset at the time this work was launched. A more powerful approach would have been to conduct a comprehensive meta-analysis of the four populations. An international initiative has been set up to overcome this limitation. Another caveat is that the diabetic nephropathy phenotype was defined by the presence of proteinuria, regardless of renal function, and genetic susceptibility to proteinuria might differ from genetic predisposition to renal failure. However, the diabetic nephropathy cohorts we used all had this combined diabetic nephropathy phenotype permitting international collaboration.
In conclusion, our study provides preliminary support for SORBS1 as a new susceptibility gene for diabetic nephropathy. 
